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Abstract
Cell plasticity regulated by the balance between the mesenchymal to epithelial transition (MET) and the opposite
program, EMT, is critical in the metastatic cascade. Several transcription factors (TFs) are known to regulate EMT,
though the mechanisms of MET remain unclear. We demonstrate a novel function of two TFs, OVOL1 and OVOL2,
as critical inducers of MET in human cancers. Our findings indicate that the OVOL-TFs control MET through a
regulatory feedback loop with EMT-inducing TF ZEB1, and the regulation of mRNA splicing by inducing Epithelial
Splicing Regulatory Protein 1 (ESRP1). Using mouse prostate tumor models we show that expression of OVOL-TFs
in mesenchymal prostate cancer cells attenuates their metastatic potential. The role of OVOL-TFs as inducers of
MET is further supported by expression analyses in 917 cancer cell lines, suggesting their role as crucial regulators
of epithelial-mesenchymal cell plasticity in cancer.
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Introduction
More than 90% of cancer-related deaths result from
metastasis [1]. Consequently, we must further our
understanding of the mechanisms driving cancer progression
and metastasis. Epithelial to mesenchymal transition (EMT),
and the converse process of MET, are crucial programs
involved in wound healing and early organ development [2].
EMT and MET may also play critical roles in both cancer
progression and establishment of metastatic colonies [3]. When
cancer cells undergo EMT, they acquire the ability to dissociate
from the primary tumor and enter circulation. These circulating
cells are then capable of disseminating and undergoing MET,
resulting in metastatic tumors. Understanding this phenotypic
plasticity is one key to hindering cancer progression [4].
EMT is linked to alterations in gene expression and
morphology and is associated with downregulation of cell
adhesion proteins, such as E-cadherin (E-cad). This process
allows cancer cells to dissociate from their neighbors while
increasing their motility [5]. It has been proposed that EMT is
regulated by reciprocal feedback loops between ZEB1/ZEB2
TFs and members of the MicroRNA miR-200 family [6,7].
Specifically, ZEB1 can induce EMT by repressing epithelial
proteins and by downregulating its own miR-200 repressors. At
the same time, miR-200s repress ZEB1 as well as stem cell
factors and epigenetic regulators involved in EMT. It is thought
that these reciprocal feedback loops are responsible, in part,
for the phenotypic plasticity exhibited in cancer and metastasis
[4].
Other proteins may serve as regulators/inducers of EMT or
potential biomarkers for mesenchymal cells. Induction of EMT
has been associated with TGFβ expression [8]. In part, this
occurs via upregulation of ZEB1/2, which, in turn, inhibits
epithelial splicing regulatory proteins (ESRP) [9].
Downregulation of ESRP, and the resulting repression of
alternative splicing, has been shown to be crucial in EMT. For
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example, in breast cancer, repression of ESRP results in a
switch in CD44 isoform expression that is critical in the
induction of EMT and cancer progression [10].
Despite our growing knowledge regarding EMT, the
mechanisms mediating MET are far less understood. Using two
models of prostate and breast cancer mesenchymal cells, we
discovered that TFs OVOL1 (OVO-like 1, Entrez Gene ID
5017) and OVOL2 (Gene ID 58495) are associated with MET
in our models, as well as in other cancers. OVOLs are zinc-
finger TFs that act as regulators of embryogenesis [11–13]. We
first analyzed how OVOLs control expression of EMT-inducing
TFs and ESRPs. We then studied how MET, induced by the
OVOL-TFs, correlates with key factors of epithelial cell
development in 917 cancer cell lines that conform to the
Human Cancer Cell Encyclopedia [14], and investigated the
implications of MET in the regulation of cancer cell invasion
and metastasis.
Results
Stable mesenchymal cells isolated from stable
epithelial prostate cancer cells co-cultured with
macrophages
To study the mechanisms of EMT in prostate cancer
metastasis we first generated an epithelial model cell line
derived from luciferase positive prostate cancer epithelial PC3
cells. We isolated a subpopulation of cells expressing
luciferase that showed a stable epithelial phenotype in culture
and designated them PC3-Epi. These cells were selected
based on two criteria: bioluminescent intensity and epithelial
cell morphology. Consistent with the epithelial state, PC3-Epi
cells maintained high E-cad, low Vimentin, and undetectable
expression of the EMT-activator ZEB1 (Figure 1A and 1B).
We next developed a mesenchymal model from PC3-Epi
cells, through interactions with macrophages. We hypothesized
that this would be possible because macrophages represent
one of the major inflammatory cell-infiltrates in the tumor
microenvironment and they have been implicated in metastasis
[15,16]. Co-culture of IL4-treated CD14+ monocytes (M2-
macrophages) with PC3-Epi for four days induced strong
morphologic alterations consistent with EMT, with concomitant
decline in the expression of E-cad and increase in Vimentin
(Figures S1A and S1B). From these cells we isolated
mesenchymal sub-populations designated as PC3-EMT1, PC3-
EMT2, PC3-EMT12, PC3-EMT14 and PC3-EMT17. These
mesenchymal cells demonstrated a striking phenotypic
alteration and expression of ZEB1, which was stably
maintained in culture (Figure 1A and 1B). Compared to the
parental epithelial PC3-Epi the mesenchymal cells expressed
lower levels of the epithelial cell adhesion molecule EpCAM;
however, still about 45% of the cells expressed EpCAM in the
cell surface as demonstrated by flow cytometry (Figure S1C).
To assess gene expression changes related to EMT we
performed three microarray analyses, comparing PC3-EMT1,
PC3-EMT12 and PC3-EMT14 to PC3-Epi. We identified a
signature of 867 genes that show changes in expression (by 2
fold or more) in all three comparisons, (VD-I, Figure 1C). We
used Ingenuity Pathway Analysis (Ingenuity Systems,
www.ingenuity.com) to ascertain the most significantly enriched
molecular functions associated with this signature: ‘cellular
movement’, ‘cellular growth and proliferation’, ‘cell-to-cell
signaling and interaction’, and ‘cell death’ are all consistent with
EMT (Table S1). ZEB1, which was upregulated in all three
comparisons, has been widely implicated in EMT and
maintenance of the mesenchymal state [2,7]. Other EMT-
inducing transcription factors like Snail, Slug or Twist1,
frequently implicated in tumorigenesis and metastasis [2], were
not identified among the common EMT signature of 867 genes
described above. Therefore to understand the role of ZEB1 in
the EMT cell program, we transfected two mesenchymal lines
(PC3-EMT1 and PC3-EMT14) with one of two lentiviral ZEB1-
shRNAs vectors: sh2 and sh4, plus the scrambled control
(Scr). Consistent with ZEB1’s role in EMT and maintenance of
the mesenchymal state, silencing of ZEB1 induced MET in
PC3-EMT1 and PC3-EMT14, with corresponding changes in
cell morphology (Figure 1D). Furthermore, sh2 and sh4
induced a striking decline in ZEB1, corresponding to
upregulation of E-cad (Figure 1E). These experiments strongly
suggest an essential role of ZEB1 in the EMT state of these
cells. When the set of differentially expressed genes in sh4-
transfected cells was matched to the EMT signature (VD-I), we
found expression changes in 50 genes that correlate with MET
transformation (VD-II, Figure 1C). This signature showed
opposite regulation when the cells were transfected with ZEB1-
shRNA sh4, relative to the scrambled control (Figure 1F). This
approach also identified a set of 4 TFs significantly
downregulated in the mesenchymal cells and upregulated by
ZEB1-shRNA: IRF6, ANKRD22, EHF and OVOL2.
OVOL1 and OVOL2 regulate MET in the prostate cancer
model
Given the observed changes in expression of IRF6,
ANKRD22, EHF and OVOL2 in EMT, as well as the observed
feedback between ZEB1 and these TFs, we speculated that
the stable EMT characteristics maintained during propagation
of PC3-EMT1 and PC3-EMT14 cells are a result of a regulatory
feedback loop. Equally, since these genes were downregulated
in EMT, overexpressing them may induce MET. We assessed
the role of each of the 4 upregulated TFs individually by
transducing PC3-EMT14 cells with lentiviral overexpressing
constructs. The expression of these 4 TFs in the EMT cells
demonstrated that OVOL2 appeared to regulate MET, as
observed by a change in cell morphology. Given the strong
parallels between OVOL2 and OVOL1, as well as OVOL2’s
apparent role in MET, we further considered whether OVOL1
may have a role in MET. Though OVOL1 did not meet the 2-
fold threshold to be included in the microarray gene signature
of ZEB1 knockdown-cells, the qPCR analysis showed that it is
highly upregulated in the epithelial PC3-Epi cells and following
ZEB1 silencing compared to the mesenchymal PC3-EMT14
(Figure 2A and Figure S2A). Therefore, we also examined the
expression of OVOL1 in the mesenchymal PC3-EMT14 cells.
Overexpression of both OVOL1 and OVOL2 induced a marked
transformation of cell morphology and a parallel increase in E-
cad expression (Figure 2B and 2C). Furthermore, both OVOLs
increased expression of ESRP1 (Figure 2C, left panel) [17]. By
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qPCR we then analyzed the changes in the expression of
several EMT-inducing transcription factors: ZEB1, ZEB2, Snail,
Slug and Twist1 (Figure 2C, right panel). Among these factors
ZEB1, ZEB2 and Slug revealed a significant decrease in
expression, which correlates with MET. We confirmed that
expression changes seen in OVOL1 and OVOL2 correspond to
changes in protein levels by Western blot (Figure 2D). We then
compared cell lysates from OVOL1 and OVOL2-
Figure 1.  Mesenchymal cancer cell populations isolated from co-cultures of epithelial prostate cancer cells and human
macrophages.  (A) Bright-phase microscopy: morphology changes in the mesenchymal cells PC3-EMT1, PC3-EMT12 and PC3-
EMT14 as compared to the epithelial PC3-Epi prostate cancer cells. Scale bars are 200 µm.
(B) Immunoblot: Expression of EMT markers in mesenchymal cancer cell lines PC3-EMT1, -EMT2, -EMT12, -EMT14 and -EMT17
compared to epithelial PC3-Epi.
(C) Microarray: Gene expression analyses comparing mesenchymal to epithelial cancer cell lines. Venn diagram-I (VD-I) depicts a
common EMT-associated signature expressed in the mesenchymal cancer lines PC3-EMT1, -EMT12 and -EMT14 compared to
epithelial PC3-Epi. VD-II – Gene signature from VD-I intersected with the signature of ZEB1 silenced cells PC3-EMT1 and -EMT14
using the shRNA-sh4, relative to scramble (Scr) control shRNA.
(D) Bright-phase microscopy: PC3-EMT14 cells transfected with ZEB1-shRNAs: sh2, sh4, or Scr. Scale bars are 100 µm.
(E) Immunoblot: Expression of EMT markers in PC3-EMT1 and -EMT14 transfected with ZEB1-shRNAs compared to Scr or non-
transfected controls.
(F) Heat map: 50 genes signature identified in VD-II (panel C). Upregulated genes are in red, downregulated in blue. Fold changes
in mesenchymal cancer cells are relative to epithelial PC3-Epi, and in sh4-transfected cells are relative to the Scr control.
The immunoblots shown are representative of two independent experiments with similar results. See also Figure S1 and Table S1.
doi: 10.1371/journal.pone.0076773.g001
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overexpressing cells to PC3-Epi, PC3-EMT14-EV, and cells
overexpressing the TFs IRF6 and ANKRD22, also regulated by
ZEB1 (Figure 1F). Rescue of E-cad and loss of Vimentin were
induced in both OVOL-overexpressing cells, while no
significant change was observed in the cells expressing other
TFs (IRF6 and ANKRD22) (Figure 2E). Although qPCR
reflected a significant change in Slug expression, the Western
did not show a change at the protein level in the OVOL
overexpressing cells, suggesting that translational regulation
might play a role in Slug levels. Of the five TFs tested, these
results indicate that OVOL1 and OVOL2 are key inducers of
MET in these cells.
To understand the implication of OVOL-mediated MET in the
invasive potential of mesenchymal PC3-EMT14 cells, we used
Boyden chamber assay on cells overexpressing OVOL1/2.
Both OVOLs significantly affected the invasion capacity of
PC3-EMT14. In the case of OVOL1, we observed reduced cell
migration, which affected the ratio of invasion vs. migration
(invasion index) (Figure 2F). OVOL2 overexpressing cells
demonstrated a significant decline in both invasion and
migration, with a highly reduced invasion index. These results
support the role of OVOL1 and OVOL2 in decreasing migration
and invasion, as expected for MET reprogrammed cells.
We next used shRNAs for OVOL1 (shOVOL1-a, -b, -c) and
OVOL2 (shOVOL2-d, -e, -f), to reduce their expression in
epithelial PC3-Epi cells (Figure 2G). None of the shRNAs
affected E-cad expression. However, in cells with decreased
OVOL2 expression, we observed a significant upregulation (up
to 3-fold) of ZEB1 mRNA. These results suggest that a 3-fold
change in ZEB1 expression is not sufficient to induce EMT in
PC3-Epi cells. Moreover, as observed by qPCR, the
expression of ZEB1 is over 20 fold higher in PC3-EMT14
compared to PC3-Epi cells (Figure S2A). Furthermore given
the similar function of OVOL1 and OVOL2 in the induction of
MET it is tempting to speculate that they could substitute for
one another. This may explain why a knockdown of only one of
the OVOL is not sufficient to induce a significant change in E-
cad. To test this possibility we performed a double knockdown
with shRNAs for each of the OVOL-TFs. Although no selection
of transfected cells was possible (both shRNA constructs
expressed GFP), a total population of cells transfected with
shOVOL1-a and shOVOL2-d (shOVOL1/2-a/d) demonstrated a
significant upregulation of vimentin and a partial decrease in E-
cad compared to the control PC3-Epi-NS cells (Figure 2H).
Overall, these findings suggest a critical role of both OVOLs in
maintaining the epithelial state of these cells and therefore, a
double knockdown would be required to induce and maintain
the mesenchymal state. Consequently, a greater knockdown of
OVOL1 and OVOL2 would induce a more complete EMT
transformation in cancer cells.
Other experiments in prostate cancer cells induced to
undergo EMT led to similar findings concerning the regulation
of the OVOL and ZEB1 TFs. For example, the transmembrane
protein Tetraspanin-8 (TSPAN8) was identified in the signature
shown in Figure 1F as a gene upregulated in EMT cells and
downregulated by ZEB1-shRNA. Overexpression of TSPAN8 in
the epithelial PC3-Epi and DU145 cells led to partial EMT
transformation characterized by the upregulation of ZEB1 and
the downregulation of the OVOL TFs in both cell lines (Figure
S2B-E).
A transcriptional repressor function of OVOL2 was previously
shown in keratinocytes, where OVOL2 repressed c-Myc and
Notch1 [18]. Since ZEB1 expression significantly increased in
cells with decreased OVOL2 (Figure 2G), we tested if OVOL2
directly interacts with the ZEB1 promoter. We performed
chromatin immunoprecipitation (ChIP) targeting the ZEB1
promoter in PC3-EMT14-OVOL2 and control cells with two
antibodies, anti-OVOL2 and anti-V5-tag. We designed 7
TaqMan primers and probes spanning the promoter from -4848
to +530 bp (Figure 2I) and found several potential OVOL2
binding sites: 5’-A(A/T) (A/T) (C/A) (T/C)GTTA(T/A) [18]. With
both antibodies, we observed over 50-fold enrichment for the
same primer/probe-position (+382/+530) when comparing
OVOL2-expressing and control cells (Figure 2J and Figure
S2B). In contrast, input chromatin of both cell-types showed
similar amplification with all primer-pairs. These results indicate
specific binding of OVOL2 to the ZEB1 promoter at the +325
region, where one OVOL2 consensus site was identified
(Figure 2I). In addition, since no specific chromatin fragment
was amplified with -115/+29 primers, it is unlikely that OVOL2
binds to the +115 site, another potential site in the proximal
region (Figure 2I). Fragment +123 -(-115) = 238 bp is
significantly smaller than +530 – (+115) = 415 bp; but about the
same size as + 530 – (+325) = + 205 bp. Therefore, a binding
to the +115 site would imply a specific pull-down of a chromatin
fragment that should be detected with the -115/+29 primers.
Together with the shRNA and expression data, these findings
suggest that OVOL2 acts as a direct transcriptional repressor
of ZEB1.
Mesenchymal cells form mesenchymal tumors in vivo
To determine the tumorigenic potential of PC3-EMT12 and
PC3-EMT14, we subcutaneously inoculated
immunocompromised NSG mice. Both mesenchymal cancer
cell lines formed predominantly mesenchymal-type tumors
characterized by low E-cad and high ZEB1, while PC3-Epi
tumors showed high E-cad and low ZEB1 expression (Figure
S3A). We saw no significant differences in tumor growth rates
between the groups (Figure S3B). To assess the metastatic
potential of the mesenchymal cells, we used the intracardiac
injection (ICI) mouse model of cancer metastasis [19]. We
observed more mice with metastasis in multiple sites in the
groups injected with PC3-EMT12 or PC3-EMT14 cells (Figure
3A). They also showed a higher overall tumor burden (about
one order of magnitude) and decreased mouse survival, in
comparison to mice injected with parental PC3-Epi cells (Figure
3B and Figure S3C). Simultaneous staining with E-cad and
ZEB1 antibodies demonstrated that metastatic PC3-EMT12
and PC3-EMT14 tumors displayed typical mesenchymal
characteristics (low E-cad and high ZEB1), while metastatic
tumors from PC3-Epi cells displayed predominantly epithelial
characteristics (high E-cad and low ZEB1) (Figure 3C and
Figure S3D-E). Our findings suggest that mesenchymal cells
(PC3-EMT12 and PC3-EMT14) form metastases that maintain
the mesenchymal phenotype. Notably, some metastatic tumors
from PC3-Epi cells exhibited both mesenchymal and epithelial
OVOL1 and OVOL2 Induce MET in Human Cancer
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e76773
Figure 2.  OVOL1 and OVOL2 induce MET in mesenchymal prostate cancer cells.  (A) qPCR: mRNA expression in PC3-
EMT14-sh4 relative to PC3-EMT14-Scr.
(B) Bright-phase microscopy: PC3-EMT14 cells expressing OVOL1 and OVOL2 exhibit an epithelial phenotype as compared to the
parental PC3-EMT14. Scale bars are 100 µm.
(C) qPCR: Expression of the epithelial cell markers E-cad and ESRP1, and the EMT-inducing TFs ZEB1, ZEB2, Slug, Snail, and
Twist1 in PC3-EMT14 cells expressing OVOL1 and OVOL2 relative to the empty-vector (EV) control.
(D) Immunoblot: OVOL1 and OVOL2 protein expression in transfected cells was confirmed by using OVOL1 or V5-specific
antibodies, respectively.
(E) Immunoblot: Expression of epithelial marker E-cad and mesenchymal markers ZEB1 and Vimentin. Changes in Slug expression
were minimal and did not correlate with MET. PC3-EMT14 cells expressing IRF6 or ANKRD22, EV and epithelial PC3-Epi are
controls.
(F) Invasion/migration assay: Representative images and graphs of cancer cell invasion using a Boyden chamber assay. Bar graphs
of OVOL1 and OVOL2 expressing PC3-EMT14 cells relative EV. Percent invasion represents the ratio invading/migrating cells. The
graph is representative of one out of three independent experiments.
(G) qPCR: Expression of PC3-Epi cells transfected with OVOL1-shRNAs (a, b, c) or OVOL2-shRNAs (d, e, f), relative to the non-
silencing control PC3-Epi-NS (represented by the dashed line).
(H) Immunoblot: PC3-Epi cells transfected with both OVOL1 and OVOL2 shRNAs (sh-OVOL1/2) demonstrate a decrease in E-cad
and increase in Vimentin, which suggests a partial EMT transformation.
(I) Schematic: The ZEB1 promoter with potential OVOL2 binding sites (orange triangles) according to the general consensus: 5’-
A(A/T) (A/T) (C/A) (T/C)GTTA(T/A). Designed TaqMan primer-pairs are shown as black arrows. Numeration is relative to the
transcriptional start site (+1). The sequence of a putative OVOL2 binding site that corresponds to the ChIP DNA in the OVOL2
expressing cells is at +320.
(J) ChIP qPCR: (Left) shows input chromatin of PC3-EMT14-OVOL2 relative to EV, and demonstrates that similar amounts of DNA
were used (Right). depicts the ChIP DNA using OVOL2 antibody. Primers are named after their forward primer (see panel I).
Results were normalized to input controls. The graph depicts one representative experiment out of three with similar results.
qPCR results were normalized to β –actin. Graphs show mean +/- sem; p-values are represented as * p < 0.05; ** p < 0.01; *** p <
0.001. The qPCRs and immunoblots are representative of two independent experiments with similar results. See also Figure S2.
doi: 10.1371/journal.pone.0076773.g002
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characteristics, though a majority of the PC3-Epi tumors
demonstrated the epithelial phenotype (Figure 3C). Figure 3C
shows a mouse injected with PC3-Epi cells, where a tumor in
the left femur was predominantly mesenchymal type, while the
tumor in the right displayed a highly epithelial phenotype.
Importantly, we found similar mesenchymal-epithelial cell
plasticity in a metastatic tumor isolated from the femur of a
patient with advanced prostate cancer. IHC staining of tumor
sections with E-cad and ZEB1 antibodies showed regions with
both highly epithelial (high E-cad, low ZEB1) and with
mesenchymal characteristics (low E-cad and high ZEB1)
(Figure 3D).
According to the results shown in Figure 2B-E, the effect of
OVOL1 overexpression is similar to OVOL2. They both induce
MET and ZEB1 downregulation. In addition ZEB1-shRNA
induces the expression of both OVOL1 and OVOL2 and MET
in the mesenchymal PC3-EMT14 cells (Figure 2A). To
elucidate the role of OVOL TFs in the metastatic potential of
the cells, we inoculated mice via ICI with epithelial cells
overexpressing OVOL1 (PC3-EMT14-OVOL1), ZEB1-shRNA
(PC3-EMT14-sh4) or the scrambled control (PC3-EMT14-Scr).
We assessed tumor progression by bioluminescence and
observed that induced MET in PC3-EMT14 cells significantly
reduced metastatic potential. Both ZEB1-shRNA and OVOL1
expression reduced the number of mice with tumor metastasis
in multiple sites (Figure 3E). Furthermore, the overall tumor
burden declined significantly when compared to mice injected
with PC3-EMT14-Scr control cells (Figure 3F). IHC staining of
metastatic tumors with E-cad and ZEB1 revealed that MET had
occurred in tumor cells that express OVOL1 or ZEB1-shRNA,
as indicated by positive E-cad and lowered ZEB1 expression in
contrast to the mesenchymal control cells (Figure 3G).
OVOL-induced MET reduces the metastatic potential of
mesenchymal cancer cells
To further investigate the metastatic potential of the OVOL-
expressing cells, we used an orthotopic mouse model of
prostate cancer [20]. In bioluminescence analysis, we saw a
similar total tumor burden (ROIs) in all groups (Figure 4A).
Twenty-eight days after inoculation, the number of mice with
metastases was significantly lower in the group injected with
OVOL-expressing cells (Figure 4B and 4C). We resected
primary tumors 42 days after inoculation, recorded their
weights, and analyzed tumor sections by IHC. Orthotopic
prostate tumor weights were significantly higher in mice
inoculated with PC3-EMT14-OVOL2, while mice injected with
control PC3-EMT14 cells showed the lowest weights (Figure
4D). The observed decrease in metastatic potential for OVOL-
expressing cells in our model correlates with a previous report
showing that mice with larger orthotopic prostate tumors had a
reduced metastatic burden [20].
IHC staining of the tumors revealed that PC3-EMT14 tumors
(orthotopic and metastases) are predominantly mesenchymal
and are mostly negative for E-cad expression and positive for
ZEB1 (Figure 4E and Figure S4A). These mesenchymal cells
can proliferate and form metastasis. This was further
demonstrated by Ki67 positive staining of E-cad negative cells
in metastatic tumor sections of PC3-EMT14 mice (Figure S4B).
Although we cannot exclude the possibility of transient MET
followed by EMT, these findings suggest that mesenchymal
cells do not need to undergo MET to colonize the tumor. In
contrast, the OVOL-expressing cells formed orthotopic tumors
and metastases with strong epithelial phenotype, characterized
by high expression of E-cad and lowered ZEB1; which strongly
suggests that the OVOL-TFs induce and stabilize MET in these
cells (Figure 4E and Figure S4A).
OVOL TFs orchestrate a transcriptional and splicing-
regulatory program that induces MET in human cancer
cells
We next looked for consistent results using tissue-cDNA
arrays from sections of human prostate cancer tumors (n = 40),
by evaluating expression of E-cad, OVOL1, and OVOL2. To
demonstrate the correlation between E-cad and OVOL-
expression we normalized each sample value to the average
value for all tumor samples. We observed strong correlation
between E-cad and OVOL1 (r = 0.66) and OVOL2 (r = 0.7) in
all tested prostate tumor tissues (Figure 5A).
Using Oncomine (Compendia Bioscience, Ann Arbor, MI) we
assessed the generality of our results across multiple cancer
cell lines. The Adai Cell Line (206 cancer cell lines, 27 cancer-
types), Wooster Cell Line (314 lines, 107 cancer-types), and
Barretina Cell Line (917 lines, 178 cancer-types) [14], all
demonstrated high correlation in expression between the
OVOL TFs and both E-cad and ESRP1, as well as other genes
in the MET signature shown in Figure 1F (Figure S5A and
Table S2). In addition, the 917 cancer cell-lines in the Barretina
study show high correlation between the expression of OVOL1
and OVOL2 (r = 0.76).
Following-up on the expression differences observed
between epithelial and mesenchymal cells in the microarray
study, we used RNA-seq to explore differential gene
expression across PC3-Epi, PC3-EMT14, PC3-EMT14-OVOL1
and PC3-EMT14-OVOL2 cells. OVOL expression induced
profound changes in the cell transcriptome as compared to the
parental mesenchymal PC3-EMT14 cells. A common gene
signature for this transition revealed 277 genes that correlated
with MET (Figure 5B). We observed a strong correlation in
gene expression across the epithelial cells (Figure 5C) and
changes in the top 100 genes are shown in Figure S5B.
ConceptGen analysis [21] revealed enrichment for concepts
consistent with MET (Table S3).
To test the roles of OVOL-TFs in MET, as well as the
potential function of OVOL2 as a transcriptional repressor of
ZEB1, we correlated our RNA-seq results with gene expression
in multiple cancer cell lines (Barretina study). We only
considered genes that showed a positive (r > 0.5) or negative (r
< -0.5) correlation with OVOL-TF expression. For the positive
correlation, we identified 129 genes that correlate with both
OVOL TFs, suggesting a concurrent role in MET. Importantly,
67 of the 129 genes are induced by both OVOL1 and OVOL2,
and show high correlation in E-cad expression (Figure 5D).
ConceptGen analysis of this 67 gene-signature revealed a list
of 18 annotated genes with functions related to MET (Figure
5E). These genes are involved in regulation of intercellular
junctions, tight junctions, cell polarity, desmoplakins and
OVOL1 and OVOL2 Induce MET in Human Cancer
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Figure 3.  Mesenchymal cancer cells show increased metastasis while not requiring MET for solid tumor formation.  (A)
Metastasis: The percentage of ICI-inoculated mice with multiple luciferase signals at 21 and 35 days.
(B) Tumor burden: Mice received ICI and were imaged weekly for 35 days. Luciferase expression is represented as regions of
interest (ROI-photons/s).
(C) IHC: Simultaneous ZEB1 and E-cad staining of metastases detected in the femur and liver of PC3-Epi or PC3-EMT14 injected
mice. Note the mesenchymal (ZEB1high / E-cadlow) (black arrows) and epithelial (ZEB1low / E-cadhigh) (green arrows) cancer cells,
depicting the EMT/MET plasticity in subpopulations of PC3-Epi and PC3-EMT14. Scale bars are 100 µm (black) and 20 µm (red).
(D) IHC: ZEB1 or E-cad staining of metastasis from the femur of a patient with advanced prostate cancer. Note the mesenchymal-
like (ZEB1high (black arrows)/ E-cadlow (yellow arrows)) and epithelial (ZEB1low / E-cadhigh (green arrows)) cancer cells. Scale bars
shown represent 100 µm (black bar) and 50 µm (red bar).
(E) Metastasis: The percentage of ICI-inoculated mice with multiple luciferase signals at 21 and 35 days.
(F) Tumor burden: Mice received ICI and were imaged weekly for 35 days. Luciferase expression is depicted as regions of interest
(ROI-photons/s).
(G) IHC: ZEB1 or E-cad staining of metastases in ICI-mice. Note the higher E-cad and lower ZEB1 expression in the metastatic
cells expressing OVOL1 or ZEB1-shRNA (sh4). Scale bar represents 100 µm.
Graphs show mean +/- sem; p-values were calculated and represented as * p < 0.05; ** p < 0.01. All IHC images are representative
of one out of three sections showing similar results. See also Figure S3.
doi: 10.1371/journal.pone.0076773.g003
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desmosomes and genes related to epithelial-specific
expression. Six of the 67 genes are not annotated in
ConceptGen, including ESRP1 and EPCAM, both of which
show high correlation with expression of both OVOLs. The
negative correlation set includes 22 genes (Table S4). In this
list we identified factors that induce EMT or are known markers
of mesenchymal cells, including ZEB1 (r = -0.7), ZEB2 (r =
-0.62) and Vimentin (VIM) (r = -0.7). Interestingly TGFβ1 (r =
-0.53) negatively correlated only with the expression of OVOL2.
Furthermore, from the genes that inversely correlate with
Figure 4.  OVOL-induced MET reduces the metastatic potential of mesenchymal PC3-EMT14 in vivo.  (A) Tumor burden:
Luciferase expression is depicted as regions of interest (ROI-photons/s) in mice with orthotopic injections.
(B) Metastasis: (Left) the percentage of orthotopically inoculated mice with multiple luciferase signals at 21 and 28 days (Right).
depicts the total number of metastases per group divided by the number of mice (n) per group at 28 days.
(C) Imaging: Representative images of luciferase expression in mice 28 days after receiving orthotopic injections. Metastases for
each group are circled in red in either the ventral or dorsal images and excluding those suspected to correspond to the same tumor.
(D) Tumor Weight: The average weights of orthotopic (prostate) tumors resected at 42 days (n = 4).
(E) IHC: E-cad, and ZEB1 staining of metastatic tumors in mice that received orthotopic injections from each group inoculated with
OVOL expressing cells or control PC3-EMT14. Note the higher E-cad and lower ZEB1 expression in OVOL-expressing cancer cells.
Scale bar represents 100 µm. The IHC shows a representative staining of one out of three sections with similar results.
Graphs show mean +/- sem; p-values were calculated and represented as ** p < 0.01. See also Figure S4.
doi: 10.1371/journal.pone.0076773.g004
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Figure 5.  OVOL expression correlates with the epithelial cell state in multiple human cancer cell lines.  (A) qPCR: cDNAs
from human primary prostate cancer tissues (n = 40; Origene) was analyzed for the expression of E-cad, OVOL1 and OVOL2. The
results were normalized to β-actin and shown relative to the average of all cancer samples for each gene as: .
log ((Value of Gene (X) for a Sample) / (Value of Gene (X) for Average Cancer)). The sample values are shown in the dot plots and
the correlation of OVOL1 or OVOL2 expression with E-cad was calculated (r). The graph depicts a representative experiment out of
two with similar results.
(B) Venn diagram: Depicts the RNA-seq results of differentially expressed genes common in the OVOL expressing cells and PC3-
Epi, relative to PC3-EMT14. The intersection of A and B represents a common epithelial transcriptional signature of 277 genes. The
RNA-seq data was analyzed from at least two biological replicates for each cell line.
(C) Dot plot: Expression correlation analyses of the 277 genes identified in the epithelial signature from panel (B). Correlation is
depicted between PC3-Epi, PC3-EMT14-OVOL1 or PC3-EMT14-OVOL2.
(D) Venn diagram: Compares the results from panel (B) with the genes that correlate with the expression of the OVOLs in 917
human cancer cell lines. From the 129 genes that correlated (r > 0.5) with the OVOLs expression in the 917 cancer cell lines, 67
genes are induced by the expression of both OVOL1 and OVOL2 in PC3-EMT14 (C intersection D).
(E) Heat map: ConceptGen analysis of the 67 gene-signature from panel (D) revealed a list of 18 annotated genes with functions
related to the epithelial state of the cells.
(F) Table: 45 genes negatively correlated with OVOL2 expression (r < -0.5) across 917 cancer cell lines. Among these 45 genes,
the 10 shown are also downregulated by OVOL2 expression in PC3-EMT14. Note the TF ZEB1 and the mesenchymal marker
vimentin (VIM) are the top genes in this list.
See also Figure S5 and Tables S2, S3, and S4.
doi: 10.1371/journal.pone.0076773.g005
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OVOL2, 10 genes are downregulated by OVOL2 expression in
PC3-EMT14 (Figure 5F). Notably, ZEB1 is the most negatively
regulated gene in this list.
Alternative splicing is among the most important gene
regulatory mechanisms in EMT-MET [22]. This post-
transcriptional regulation acts in concert with other regulations
to control transitions between the epithelial and mesenchymal
states. Accumulating evidence suggests that alternative
splicing is largely orchestrated by ESRP1 and ESRP2 [10,17].
Our study shows that the ESRPs are regulated by the OVOLs
in mesenchymal cancer cells, and that their expression
correlates with the OVOLs in the Barretina study: r = 0.76 with
OVOL1 and r > 0.81 with OVOL2.
Interestingly, when analyzing the RNA-Seq results for genes
that did not show overall expression changes, but showed
significant isoform switching, we found that OVOL1 and
OVOL2 induced post-transcriptional splicing of 15 and 237
genes, respectively. However, isoform switching of only five
genes was regulated by both TFs: CD44, ENAH, IP6K2,
LGALS8 and GPR126. Further comparisons between PC3-Epi
and PC3-EMT14 cells identified 50 genes whose splicing
regulation was induced by OVOL expression (Table 1). Three
of five isoforms regulated by both OVOL TFs were also
common to PC3-Epi cells: CD44, ENAH and IP6K2. Both CD44
and ENAH are regulated by ESRPs, showing differential
splicing in epithelial versus mesenchymal cells [22]. Among the
50 splicing isoforms induced by OVOL TFs and also regulated
in epithelial cells, 11 were expressed exclusively in either
mesenchymal or epithelial cells (Table 1). Intriguingly, one of
the genes showing a switch in isoforms, EPB41L5, is required
for EMT during mouse gastrulation, and regulates E-cad post-
transcriptionally (Figure S5C) [23,24]. This regulation of
EPB41L5 suggests that splicing may play additional roles in
OVOL-induced MET.
OVOL-TFs induce MET and reduce invasive potential in
a breast cancer model
To test these results in a context outside of prostate cancer,
we next used the poorly differentiated (mesenchymal-type),
highly invasive, breast carcinoma MDA-MB-231 cell line [25].
These cells were transduced with lentiviruses expressing
OVOL1, OVOL2, or both. Cells expressing OVOL2 or both
showed significant changes in morphology, shown by a
decrease in mesenchymal (elongated) cells and an increase in
epithelial-like cells (Figure 6A). To test whether the observed
morphological changes were related to MET, we used qPCR to
measure the expression of E-cad, ESRP1, and the 5 TFs
previously tested: ZEB1, ZEB2, Snail, Slug and Twist [2].
Consistent with MET, we observed significant increases in E-
cad and ESRP1 expression in all OVOL-expressing cells
(Figure 6B, left panel), while ZEB1 and ZEB2 expression
significantly decreased (Figure 6B, right panel). Changes in
Snail and Slug did not correlate with MET, and Twist mRNA
was undetected. Consistent with the expression changes,
Western blot revealed a drop in ZEB1 and an increase in E-cad
proteins in OVOL-expressing cells, along with an accentuated
increase with OVOL2 (Figure 6C). Transduction with both
OVOLs increased the levels of each of the OVOL proteins,
compared to single-transduced cells, suggesting a cross-
regulation of these proteins in these cells.
As in the prostate cancer model, we used Boyden chamber
assay to assess invasion in MDA-MB-231 cells expressing
OVOL1, OVOL2, or both. In the OVOL-expressing cells,
percent invasion declined and the most striking decrease was
observed in cells expressing both TFs, indicating OVOL-
mediated MET attenuates the invasive phenotype (Figure 6D).
Given evidence of reciprocal feedback loops between
ZEB1/2 and miR-200 family members in EMT-MET
transformations [7,26], we explored the contribution of
miR-200s as potential inducers of epithelial differentiation in the
breast and prostate cancer models. In MDA-MB-231 cells
expressing the OVOLs, we used qPCR to assess expression of
miR-200 family members (miR-200a, miR-200b, miR-200c,
miR-141, miR-429, miR205, miR-203), relative to controls miR-
U6 and miR16. The double-transduced cells showed greater
than 2-fold increases in miR-200a, miR-200c, and miR-429
(Figure 6E), while only modest changes were seen in the
single-transduced cells. In particular, OVOL2-expressing cells
showed small changes in miR-200s (less than 2-fold in all
cases), which did not correlate with changes observed in E-cad
and ZEB1 protein (Figure 6C). In our prostate cancer model,
we tested the expression of miR-200s in PC3-EMT14 and the
epithelial cells: PC3-Epi, PC3-EMT14-OVOL1 and PC3-
EMT14-OVOL2. We observed significant upregulation of
miR-203 and miR-205 in epithelial cells (Figure 6F). Comparing
these observations to the MDA-MB-231 model, we found no
general correlation between the expression of OVOL and the
members of miR-200-family across cell types, suggesting that
regulation of miRNA-200s is cell-type specific. In addition,
these findings suggest that the OVOLs may indirectly regulate
some miR-200s, which could also contribute to the stability of
the epithelial state.
Discussion
The data presented here reveals a novel role for OVOLs as
important regulators of MET in cancer cells. Using a
combination of in vitro and in vivo experiments, as well as data
from cancer databases, we show that OVOLs orchestrate a
transcriptional and splicing-regulatory program that mediates
MET, resulting in decreased cancer cell invasiveness.
Furthermore, we describe a critical role for the OVOLs as
regulators of cancer cell metastasis, by repressing ZEB1 and
inducing ESRP1.
Tumor cells’ ability to invade surrounding tissues and
disseminate to distant organs requires them to activate a
program allowing them to undergo EMT, detach from the
primary tumor, enter circulation, and transit to a secondary site.
EMT is thought to be a transient program, where changes in
extrinsic signaling factors induce mesenchymal cells to revert
back to the epithelial state [4]. MET has been associated with
cancer cells’ ability to adapt to a new site, proliferate, and form
macrometastases. This hypothesis is supported by the
observation that metastases originating from epithelial cancers
show a high degree of differentiation towards the epithelial
phenotype. Meanwhile in cancer patients, heterogeneous
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Table 1. Isoforms Regulated by the Expression of OVOL1 and OVOL2.
NCBI Reference ID Gene Symbol PC3-EMT14 PC3-EMT14-OVOL1/PC3-EMT14-OVOL2 Fold Change (MET/EMT) Isoforms up in MET Isoforms up in EMT
NM_001145356 CBWD1 § 0.60 6.24 10.41 +  
NM_001005911 IP6K2 § 25.84 7.55 0.29  +
NM_001001390 CD44 §§ 2.11 12.91/12.86 6.07/6.11 +  
NM_001008493 ENAH §§ 2.08 6.13/4.81 2.91/2.31 +  
NM_016351 ADAM22 1.00 0.40 0.4  +
NM_014324 AMACR 5.29 2.35 0.45  +
NR_036556 ANKRD54 0.99 0 0  +
NM_001010986 ATP11C 4.32 1.50 0.35  +
NM_174957 ATP2A3 0.26 0 0  +
NR_024597 C11orf73 0 0.46 INF +  
NM_001001389 CD44 0.39 5.13 13.20 +  
NM_001185177 CES3 0 0.31 INF +  
NM_203356 CTAGE5 0.55 0.13 0.24  +
NM_001085460 CTNND1 12.89 5.42 0.42  +
NM_133375 DIS3L 1.50 0 0  +
NM_004432 ELAVL2 1.45 0.37 0.26  +
NM_001135023 ELMOD3* 0.35 2.49 7.06 +  
NM_001135022 ELMOD3* 3.76 1.85 0.49  +
NM_203343 EPB41 0 0.97 INF +  
NM_001184939 EPB41L5* 1.49 3.66 2.47 +  
NM_020909 EPB41L5* 1.74 0.62 0.36  +
NM_017848 FAM120C 1.86 0.92 0.5  +
NM_001015045 FAM13A 3.33 1.56 0.47  +
NM_001134456 FAM55C 5.55 2.65 0.48  +
NM_000802 FOLR1 0.06 0.32 5.44 +  
NM_001018100 GCOM1 1.14 4.52 3.96 +  
NM_001193322 IKBKE 0.90 0 0  +
NM_016291 IP6K2 6.10 0 0  +
NM_177535_1 MAGED4B 9.11 3.07 0.34  +
NM_145687 MAP4K4 22.74 10.81 0.48  +
NM_001042453 MST4 0 0.31 INF +  
NM_022764 MTHFSD 1.67 0.75 0.45  +
NM_203318 MYO18A 2.38 5.78 2.43 +  
NM_001098623 OBSCN 0.22 0.67 3 +  
NM_001128629 PAK6 3.01 6.25 2.07 +  
NM_001166109 PALLD 1.84 6.80 3.69 +  
NM_001146105 PARP9 5.53 11.41 2.06 +  
NM_001184917 PCYT2 1.10 3.14 2.85 +  
NM_153321 PMP22 13.01 5.04 0.39  +
NM_182948 PRKACB 3.74 0.90 0.24  +
NM_001164758 PRKAR1B* 1.40 4.29 3.06 +  
NM_001164759 PRKAR1B* 5.13 2.19 0.42  +
NM_002840 PTPRF 1.69 6.52 3.85 +  
NM_144489 RGS3 5.16 1.43 0.28  +
NM_138484 SGOL1 0 0.41 INF +  
NM_001135054 SIGIRR 15.50 6.13 0.4  +
NM_020428 SLC44A2* 5.89 22.83 3.88 +  
NM_001145056 SLC44A2* 28.71 5.32 0.19  +
NM_001104590 SLFN11 1.80 0.60 0.33  +
NM_001184749 SLITRK4 0.28 0.09 0.32  +
NM_001128210 SPRED2 4.30 0.37 0.09  +
NM_001198531 TCF7L2 2.05 0.74 0.36  +
NM_001167912 VEPH1 4.41 0 0  +
NM_014667 VGLL4 2.55 6.17 2.41 +  
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differentiation has been observed even in metastases from a
single patient [27]. In our studies of prostate cancer metastasis,
we discovered that some cells that form metastases do not
undergo MET, and that mesenchymal cells can proliferate to
develop mesenchymal-type solid tumors (Figure 3C and Figure
4E).
Usually, activation of EMT involves signaling between tumor
cells and neighboring stromal cells [28]. To determine the
mechanisms of MET; we developed a novel in vitro model of
prostate cancer that mimics interactions within the prostate
tumor. First, we generated a prostate cancer epithelial cell line
(PC3-Epi) that stable maintained the epithelial phenotype in
culture, while preserving their potential plasticity (EMT/MET).
Consequently, these cells predominantly originated epithelial
tumors, though they also demonstrated their plasticity to
develop into mesenchymal tumors in vivo via EMT (Figure 3C).
We showed that interactions between epithelial prostate cancer
cells with M2-type macrophages resulted in EMT, as well as
the upregulation of the EMT-inducing TF ZEB1. Subsequently,
we used this model to interrogate the mechanisms that
maintain the mesenchymal or epithelial phenotype. Microarray
analysis of three different EMT cell subpopulations (Figure 1A-
C) showed that other EMT-inducing TFs like Twist, Snail or
Slug were not commonly upregulated. Furthermore, it is known
that TGFβ on its own rarely induces EMT, despite being one of
the major factors that induces the EMT cell transformation [29].
For example Scheel et al. used an EMT induction cocktail in
combination with TGFβ1 to induce EMT in epithelial HMLE
cells [30]. Importantly, consistent with our findings, the resultant
cells demonstrated a significant induction of the ZEB1/ZEB2
TFs.
It has been suggested that ZEB1 mediates EMT-MET
plasticity through a feedback loop including the microRNA-200
family [26]. However, the regulation of MET by MET-inducing
TFs is under-studied. In our model, we found that ZEB1
silencing resulted in MET induction and the upregulation of four
TFs in mesenchymal cancer cells (Figure 1F). Therefore, we
investigated their potential roles in MET. We identified that the
expression of either OVOL1 or OVOL2 represses ZEB1, and
also discovered that ZEB1 regulates their expression (Figure
2A-E). Both OVOLs, in turn, induce ESRP1, whose function
has been demonstrated to play a role in MET [9,10].
OVOLs are zinc finger TFs that control gene expression in
various developmental processes, in multiple organisms.
These factors have been shown to reside downstream of key
developmental signaling pathways, such as Wnt and BMP/
TGFβ [11,12]. These same pathways collaborate in the
activation of EMT [30]. However little is known about the role of
the OVOLs in cancer or their regulation of MET. We
demonstrated that in primary tumors of prostate cancer
patients the expression of OVOL1 and OVOL2 highly correlate
with E-cad expression, a critical marker of the differentiation
state of these tumors (Figure 5A). We analyzed the gene
expression changes induced by the OVOL-TFs (identified by
RNA-Seq) relative to the control PC3-EMT14 cells. From this
analysis, we identified the genes that changed over 2-fold. We
compared this list with the 50 genes signature, which
comprises the changes induced by ZEB1-shRNA in the EMT
cells (Figure 1F). The results demonstrated that 43 out of 50
genes also changed upon OVOL1 expression, which closely
correlates with the MET cellular response induced by ZEB1-
shRNA. Likewise, OVOL2 induced the expression changes in
45 out of these 50 genes. These findings suggest that the
majority of the changes induced by ZEB1-shRNA in relation to
MET are also induced by the expression of the OVOL-TFs,
further supporting the significance of the cross regulation of
ZEB1 and the OVOL-TFs in MET.
To expand the investigation of the role of the OVOLs in
regulation of MET in human epithelial cancers, we analyzed
several studies compiled in the Oncomine database. Our
analysis revealed that expression of both OVOLs highly
correlates with expression of E-cad, ESRPs, as well as factors
associated with the epithelial phenotype that were upregulated
in our prostate cancer model (Figure S5B). Furthermore, this
analysis identified the same set of genes to correlate positively
with either OVOL1 or OVOL2 expression (r > 0.5) in 917
cancer cell lines. From the list of factors showing a correlation
higher than 0.74 (Table S2), we found that 18 out of 24 genes
were induced by both OVOLs in mesenchymal prostate cancer
cells. Additionally, a similar database analysis demonstrated
that both OVOLs negatively correlate with the expression of
ZEB1 and Vimentin (Table S4). The negative correlation
between expression of the OVOLs and ZEB1 in multiple
cancers indicates that the function of the OVOLs may not be
restricted to prostate cancer. We validated this mechanism in
another cancer-type by expressing the OVOL-TFs in the poorly
differentiated breast cancer MDA-MB-231 cells. Similar to our
finding in prostate cancer cells, expression of OVOLs induced
MET and high ESRP expression, while significantly decreasing
ZEB1 expression (Figure 6A-C). In this model the maximum
degree of MET was achieved by expression of both OVOLs.
Similar to the prostate model, OVOL-expression attenuated the
Table 1 (continued).
NCBI Reference ID Gene Symbol PC3-EMT14 PC3-EMT14-OVOL1/PC3-EMT14-OVOL2 Fold Change (MET/EMT) Isoforms up in MET Isoforms up in EMT
NM_139119 YY1AP1 2.08 4.91 2.36 +  
NM_001145448 ZNF200 0.50 0.15 0.3  +
Isoform expression changes in PC3-EMT14-OVOL1 or PC3-EMT14-OVOL2 relative to PC3-EMT14 (p > 0.008). All the isoforms shown were also significantly changed in
PC3-Epi relative to PC3-EMT14. Changes in isoform expression that are exclusive to PC3-EMT14-OVOL1 are marked with a single § Those that changed in both PC3-
EMT14-OVOL1 and PC3-EMT14-OVOL2 are marked in with §§ (values presented as OVOL1-value/OVOL2-value). Isoforms singularly expressed in PC3-EMT14-OVOL2
are shown without any symbols, except those expressed exclusively in either EMT (mesenchymal) or MET (epithelial), represented by *
doi: 10.1371/journal.pone.0076773.t001
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Figure 6.  OVOL1 and OVOL2 induce MET in MDA-MB-231 breast cancer cells.  (A) Bright-phase microscopy: morphology
changes in the OVO-overexpressing MDA-MB-231 cells towards an epithelial phenotype. Breast cancer cells were transfected with
OVOL1, OVOL2 or both TFs. Scales are 100 µm.
(B) qPCR: Expression of the epithelial cell markers E-cad and ESRP1, and the EMT-inducing TFs ZEB1, ZEB2, Slug, Snail, and
Twist1 in OVOL-overexpressing cells relative to control. Results were normalized to β-actin.
(C) Immunoblot: Expression of EMT markers in MDA-MB-231 cells overexpressing OVOL1 and/or OVOL2 (represented by +/- in the
table above the blot).
(D) Invasion/migration assay: Representative images and graphs of cancer cell invasion using a Boyden chamber assay. Bar
graphs depict the lower migratory and invasive potential of cells overexpressing the OVOL TFs. Percent invasion represents the
ratio invading/migrating cells. The graph depicts a representative experiment out of three with similar results.
(E) qPCR: miRNA expression in MDA-MB-231 cells overexpressing OVOL1, OVOL2, or both, relative to the control. Results were
normalized to miR-U6.
(F) qPCR: miRNA expression in PC3-Epi, PC3-EMT14-OVOL1 or PC3-EMT14-OVOL2 relative to the control (PC3-EMT14-EV).
Results were normalized to miR-16.
Graphs show mean +/- sem; p-values were calculated and represented as * p < 0.05; ** p < 0.01; *** p < 0.001. The qPCRs and
immunoblots are representative of two independent experiments with similar results.
doi: 10.1371/journal.pone.0076773.g006
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invasive potential of the MDA-MB-231 cells. These results are
consistent with previous findings showing that overexpression
of ESRPs attenuates EMT and malignancy in MDA-MB-231
cells [9]. Horiguchi et al. further demonstrated that the
expression of ESRPs in human breast cancer tissues inversely
correlated with progression and that high ZEB and low ESRP
expression characterize the more aggressive (‘basal like’)
subtype of breast cancer. Furthermore, consistent with our
data, Snail, Slug, and Twist did not show significant inverse
correlation with ESRPs. In that study, expression of ESRPs
partially induced MET in the MDA-MB-231 cells, mainly through
upregulation of E-cad. Using the same cell line, we show that
increased E-cad is achieved through overexpression of both
OVOL-TFs, which also results in downregulation of the
mesenchymal marker Vimentin. Our finding of OVOL regulation
of ESRP and ZEB1 further supports the significance of their
function in MET.
The transcriptional repressor function of OVOL2 on ZEB1 is
supported by the mRNA upregulation of ZEB1 upon OVOL2
depletion (Figure 2G), by the direct interaction of OVOL2 with
ZEB1 promoter region (ChIP assay, Figure 2I-J), and by the
depletion of ZEB1 protein and mRNA upon overexpression of
OVOL2 (Figure 2C-E and Figure 6B-C). The finding that
OVOL2 depletion (but not OVOL1) induces the upregulation of
ZEB1-mRNA (Figure 2G), suggests that OVOL2 plays a
predominant role in the regulation of ZEB1. However, the direct
regulation of ZEB1 by OVOL1 is not demonstrated and OVOL1
might regulate ZEB1 indirectly. Further investigation would be
necessary to address this issue. Nevertheless, the experiments
in MDA-MB-231 cells demonstrated that the independent
expression of each OVOL induced MET and led to depletion of
ZEB1 mRNA and protein, while combined expression of both
OVOLs further induced MET (Figure 6C). On the other hand,
depletion of both OVOL1 and OVOL2 is necessary to induce
partial EMT in PC3-Epi cells (Figure 2H). Furthermore, OVOL1
and OVOL2 are co-expressed in multiple cancer cell lines and
they induce similar gene expression profiles consistent with
MET (Figure 5B-E), which indicate analogous functions.
Altogether, these findings suggest that they could complement
each other in achieving maximum induction of MET.
Alternative mRNA splicing allows cells to create protein
isoforms with different functions from a single gene. Cancer
cells take advantage of this mechanism to produce proteins
that contribute to tumor progression, invasion, and metastasis
[31]. Thus, alternative-splicing mediated by ESRPs is a
hallmark of epithelial cell differentiation, and activation of EMT
produces isoforms associated with metastasis [22]. Warzecha
et al. showed that loss of ESRP1 induced some of the
phenotypic and protein expression changes related to EMT,
suggesting that these changes are due to alternative splicing-
mediated isoform switching [32]. As MET is essentially the
opposite of EMT, the activation of this program requires the
expression of ESRP1. Expression analysis by RNA-Seq in our
model demonstrated that OVOLs activate a splicing program
that induces isoform variants specific to the epithelial state
(Table 1). Several genes showed significant isoform switches
between MET and EMT, even though overall gene expression
did not change (Table 1). Many of these isoforms (including
CD44, ENAH, p120-Catenin, EPB41L5) show direct correlation
with both MET-EMT and metastasis, in multiple cancer types
[10,22]. Other genes demonstrated changes both in gene and
isoform-specific expression. Altogether these findings suggest
that the post-transcriptional control of gene expression is a
complement to the transcriptional regulation programs that
drive the MET/EMT transformations. Current approaches to
discover meaningful changes in alternative splicing in different
models involve manipulations with ESRPs or EMT-inducing
TFs [33]. Elucidation of OVOL-mediated splicing regulation
represents a novel approach to identify MET and EMT-
biomarkers that may help clinicians to define tumor
aggressiveness.
It has been suggested that MET regulation involves
miR-200s, whose expression directly affects cell proliferation
[4]. In our experiments with MDA-MB-231 cells, MET did not
always correlate with expression of miR-200s (Figure 6C and
6E). However, the expression of both OVOL TFs resulted in the
induction of miR-429, miR-208 and miR-200c. This suggests
that, in addition to the previously described mechanism, the
OVOL-mediated MET may involve regulation of the miR-200
family. This additional regulation could explain why more than
3-fold upregulation of ZEB1 mRNA is required to induce EMT
in the epithelial prostate cancer PC3-Epi cells (Figure 2G and
Figure S2A, S2C-D). The EMT induction requires a shift in the
balance between the MET and the EMT-inducing factors and
this could only be achieved by a significant increase in the
ZEB1 expression. The role of miRNAs in this mechanism
requires further investigation.
We propose that the mesenchymal or epithelial state of cells
is controlled, in part, by a regulatory feedback loop between the
OVOLs and ZEB1, as well as a mechanism induced by the
OVOLs to regulate mRNA splicing through ESRPs (Figure 7).
We hypothesize that when environmental conditions favor
expression of OVOLs, cells will transition towards the epithelial
state, where they are stabilized by regulatory feedback loops.
These epithelial cancer cells will have a reduced invasive and
metastatic capacity and show resistance to EMT. Alternatively,
low expression of OVOLs and high expression of ZEB1 will
induce EMT. When this mechanism is activated, the
mesenchymal state could be stabilized by regulatory feedback,
making the cells non-dormant and capable of progressing
through a colonization step. The result would be a highly
metastatic tumor in a predominantly mesenchymal state. Our
findings in xenograft models of prostate cancer further validate
our hypothesis by showing that the cancer cells demonstrate
some tumor plasticity, while the mesenchymal or epithelial
phenotypes are predominantly maintained as their states are
stabilized by the feedback loops between the OVOL-TFs and
ZEB1. This regulation may characterize the great majority of
cancer cells, as demonstrated by the high correlation between
the OVOL-TFs, ESRP1 and E-cad in addition to their inverse
correlation with ZEB1 and vimentin in 917 cancer cell lines
(Figure 5F and Figure S5A). In cancer patients, tumors may
occur as a mix of differentiated and undifferentiated cells
(Figure 3D). Together, our data improve our understanding of
cancer metastasis by revealing crucial TFs that induce MET in
cancer cells and regulate the balance between EMT and MET.
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Further investigation of the mechanisms that regulate EMT-
MET might lead to novel therapies that halt metastasis.
In summary, the findings presented here suggest a new
mechanistic model of metastatic progression in which
epithelial-mesenchymal cancer cell plasticity is mediated by the
crucial function of the OVOLs. An assessment of OVOL to
ZEB1 expression ratio may identify the trigger point for EMT-
MET in various tumor cells. However, this ratio might change,
depending on the specific cancer cell’s susceptibility (genetic/
epigenetic profile) to undergo EMT. Our future studies will
address whether OVOLs regulate additional EMT-inducing
TFs, and investigate if alternative feedback loops are activated.
It is tempting to speculate that the mesenchymal state will not
be stabilized if it is not mediated by TFs that activate a
reciprocal feedback loop.
Figure 7.  Proposed model of EMT/MET balance in human
cancer.  In human cancer cells the mesenchymal and epithelial
states are induced and maintained by transcriptional and post-
transcriptional (splicing) regulatory programs. These programs
are controlled by the feedback regulation between the OVOL
and the ZEB1 TFs, critical inducers of MET and EMT
respectively. In addition these TFs control the expression of
ESRP1, a key-splicing regulator activated in MET and
repressed in EMT. Therefore high OVOL and low ZEB1
stabilize the epithelial state decreasing cancer cell invasion and




All animal work was carried out in strict accordance with
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
University of Michigan Committee on Use and Care of Animals
approved the protocol (UCUCA- Approval Number-08434). All
surgery was performed under ketamine/xylazine or isoflurane
anesthesia and all efforts were made to minimize animal
suffering.
Cell lines
Prostate cancer PC3 and DU145 and breast cancer MDA-
MD-231 cell lines were obtained from ATCC. These cells and
all derived cell lines were cultured in RPMI-1640 (Invitrogen),
and supplemented with 10% fetal bovine serum (FBS) and 1%
Antibiotic/antimycotic (Invitrogen). Cells were passaged at 80%
confluency using 0.05% trypsin (Invitrogen).
Generation of stable epithelial PC3-Epi cells
PC3 cells were transfected with pLentilox-EV-Luc luciferase
expression vector (University of Michigan Vector Core).
Luciferin was added to culture plates and bioluminescent
imaging was done. Colonies were selected based on two
criteria: bioluminescent intensity and epithelial cell morphology.
Selection was repeated twice to ensure the majority of the cells
had luciferase activity. A stable epithelial population was
obtained and further characterized by Western blot analysis.
Isolation of stable EMT cells from macrophage co-
culture
Human peripheral blood mononuclear cells (PBMC) were
isolated as, previously described, from healthy donors,
according to HUM# 0024137 (University of Michigan Health
System) [34]. CD14+ monocytes were isolated using CD14-
magnetic beads (Miltenyi; Cat no 120-000-305) as per
manufacturer’s instructions. The CD14+ cells were forced to
differentiate into M1 or M2 macrophages upon stimulation with
INFγ (R&D; 285-IF/CF) or interleukin (IL)-4 (Humanzyme;
HZ-1004) respectively (100 ng/ml) for 36-42 hours. Previous
studies have shown this to be sufficient time to induce
macrophage differentiation into M1 or M2 types [35]. Following
the initial 36-42 hour incubation, the media was changed and
INFγ concentration was reduced to 2 ng/mL. The resulting M1
or M2 cells were co-cultured with 3x105 highly epithelial
prostate cancer cells (PC3-Epi) for 4 days. Cells were
passaged 3 times through trypsinization and 104 cells were
plated onto 10 cm tissue culture plates. A parallel culture of M2
macrophages was included to assure that no macrophage will
survive after 3 trypsinization passages. Populations showing
change in morphology were further isolated (PC3-EMT1, PC3-
EMT12, and PC3-EMT14) and characterized by Western blot
and gene expression analyses.
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Lentiviral constructs and transduction
Expression constructs.  Lentiviral plasmids were created
with the ViraPower™ II Lentiviral N-Lumio™ Gateway®
Expression System (Invitrogen) cloning system, using
manufacturer specifications. Premade entry clones were
purchased from Thermo Scientific/Open Biosystems for
OVOL2 (clone ID: 5098), IRF6 (clone ID: 2399) and TSPAN8
(clone ID: 100073674). Destination clone pLenti6.2/C-
Lumio™/V5-DEST (Invitrogen; Cat no: K370-20) was used to
construct the lentivirus plasmids and University of Michigan
Vector Core packaged plasmids into lentivirus. Overexpression
constructs for OVOL1 (clone ID: PLOHS_100067324), EHF
(clone ID: PLOHS_100070253), and ANKRD22 (clone ID:
100072173) were purchased from Thermo Scientific/Open
Biosystems.
shRNA constructs.  ZEB1-shRNAs, designated sh2, and
sh4 (clones IDs: V3LHS_356184, and V2LHS_116659,
respectively), OVOL1, designated a, b, and c (clones IDs:
V3LHS_ 400419, V3LHS_305031, V3LHS_ 47894,
respectively) and OVOL2, designated e, f, g, (clones IDs:
V3LHS_354271, V3LHS_354272, and V3LHS_60547,
respectively), non-silencing control (Cat no: RHS4348)
(OpenBiosystems), and scramble control (Lenti-pGipZ-
scramble-VSVG; University of Michigan Vector Core).
Transduction.  Cells were transduced with lentiviruses and
selected using manufacturer recommended concentrations and
protocols.
RNA isolation
RNAs were isolated from cells at ~80% confluency using an
RNeasy kit (Qiagen) and treated with DNase to remove
genomic DNA (Qiagen). RNA quality and concentration was
determined by accudrop and nanodrop (University of Michigan
Microarray core).
miRNA isolation
miRNA was isolated from cells at ~80% confluency using an
miRNeasy kit (Qiagen Cat no: 217004) following manufacture’s
protocol. RNA quality and concentration was determined by
accudrop and nanodrop (University of Michigan Microarray
core).
Microarray
Extracted mRNA was subjected to microarray analysis using
standard protocols by the University of Michigan Microarray
core for the GeneChip Human U133 Plus 2.0 (Affymetrix).
Gene expression analysis was conducted by University of
Michigan Microarray core using Bioconductor’s “Limma”
package. The microarray data “Expression profile from PC3-
Epi and derived cell lines” is accessible with the GEO ID:
GSE43489.
qPCR
cDNA was prepared using high capacity cDNA reverse
transcription kit (Invitrogen). Quantitative analysis was
performed using TaqMan Gene Expression Assays (Applied
Biosystems) with ABI 7900 HT. The following primers/probes
were used: β-actin 4352935E, OVOL1 Hs00190060_m1,
OVOL2 Hs00221902_m1, ZEB1 Hs00232783_m1, E-cad
(CDH1) Hs01023894_m1, TWIST1 Hs01675818_s1, ZEB2
Hs00207691_m1, Snail (SNAI1) Hs00195591_m1, Slug
(SNAI2) Hs00950344_m1, and ESRP1 H`s00214472_m1.
Relative Expression Calculations: In the qPCR, the target of
interest in each sample is measured using three biological
replicates. The Ct value for each biological replicate is
calculated as an average of three technical replicates. Then the
Ct value of each biological replicate is normalized to β-actin by
subtracting it from the corresponding Ct value of β-actin (-ΔCt).
The two groups of interest are compared using a Student’s t-
test. The values plotted in the graph are the average of the
base 2 anti-log transformations of -ΔCt for the biological
replicates of interest divided by the average of the base 2 anti-
log of -ΔCt for the reference group. The standard errors of the
mean are determined from these 3 values of the biological
replicates each divided by the mean for the reference group
(control cell).
TaqMan MicroRNA Assays: miR-200c TM: 002300,
miR-200a TM: 00502, miR-429 TM: 001024, miR-205 TM:
000509, miR-141 TM: 000463, miR-16 TM:000391, miR-200b
TM: 002251, miR-U6 TM: 001973, miR-423-5p TM: 002340,
miR-34b TM: 000427, miR-34a TM: 000426, and miR-34c TM:
000428. Normalization was done to either miR-U6 (MDA-
MB-231) or miR-16 (PC3-EMT14) and graphed relative to
controls specified for each case.
Origene TissueScan™ Prostate Cancer cDNA Array II
(HPRT302) was used as per manufacturer recommendations.
Samples were normalized to β-actin, and the average for each
gene was calculated among all cancer samples (average
cancer, n = 40). Each sample is plotted as a log10 of the
normalized value relative to the average cancer. Correlation
graphs of OVOL1 and OVOL2 relative to E-cad values were
constructed and Pearson coefficients were calculated using
Prism GraphPad.
Western Blot and Flow Cytometry
Protein extracts were prepared using cell lysis buffer (Cell
signaling; Cat no 9803S) with protease inhibitor (Thermo
Scientific; Cat no: 78410) and samples were analyzed by
Western blot using Invitrogen specified instructions. Western
blots were performed using anti-E-cad (cat no: 3195), anti-
ZEB1 (Cat no: 3396), anti-Vimentin (Cat no: 5741), anti-Slug
(Cat no: 9585), anti-Snail (Cat no: 3879) (Cell Signaling), and
anti-OVOL1 (Cat no: 14082-1-AP) (Proteintech Group). Anti-β-
actin (Cell Signaling; Cat no: 4970) was used as loading
control.
Flow cytometric analysis of PC3-Epi, PC3-EMT14 and PC3-
Epi-TSPAN8 were conducted as previously described [34]
using the FITC-anti-human CD326 (EpCAM) antibody (Clone
9C4, BioLegend; Cat no: 324203) or the APC-anti-human
TSPAN8 (R&D; Cat no: FAB4734A).
Microscopy.  Bright field: Images were obtained using
phase contrast on the Olympus IX71 with a mounted Olympus
DP71 camera.
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Invasion/Migration assay
Cells were trypsinized, washed once with 10% FBS, then
twice with serum free media. 5*104 cells/well were seeded in
serum-free in triplicate on top of BD Matrigel™ Invasion
Chambers (cat no: 354480) or uncoated control chambers. As
per manufacturer specifications 0.5% FBS media was placed in
the lower chamber. Staining was performed using Protocol
HEMA 3 staining kit (Cat no 122-911). Cell invasion was
assessed and quantified by averaging the counts from 5 fields
of view per well for each replicate. Cell migration was
evaluated by counting the cells that migrated to the bottom of
the uncoated insert chamber (control).
Mouse injections
ICI and subcutaneous injections with PC3-EMT12, PC3-
EMT14, and PC3-Epi were performed in NSG mice (Jackson
Laboratory) between 6-8 weeks of age. ICI studies using PC3-
EMT14, PC3-EMT14-OVOL1 and PC3-EMT14-sh4 were done
using CB17 SCID (Jackson Laboratory) male mice, between
the 6-8 weeks old. Subcutaneous injections were performed
using 2*105 cells in 200 mL matrigel:DPBS (1:1 ratio). Mice
then received injections in hind-flank, and were imaged weekly.
Intra-cardiac injections were performed using 2.5*105 cells in
0.1 mL of DPBS. Mice were anesthetized using isoflurane.
Successful injections were determined based on initial
bioluminescent imaging tumor locations. Mice with high
bioluminescent signature in areas around or in the heart during
the first 2 weeks were deemed unsuccessful, and removed
from study. Orthotopic prostate injections were performed on
male NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Jackson
labs) aged 10-13 weeks. 3*105 luciferase-positive PC3-EMT14,
PC3-EMT14-OVOL1 or PC3-EMT14-OVOL2 cells were
injected into the dorsal prostate via laparoscopic surgery. The
mice were imaged for bioluminescent signal weekly on an IVIS
200 and monitored for overall health and metastasis formation.
In vivo bioluminescent analysis and histology
Bioluminescent imaging (University of Michigan Cellular
molecular imagining core) was performed using the Xenogen
IVIS 200 and histology preparation was done as previously
described [19]. A pathologist from the University of Michigan
Pathology Core for Animal Research analyzed the
Immunohistochemistry (IHC) sections from mouse and human
tissues. IHC antibodies: anti-ZEB1 (Sigma, Cat no:
HPA027524), and anti-E-cadherin (Abcam; Cat no: ab40772).
Chromatin Immunoprecipitation.  We used Invitrogen’s
MAGnify™ Chromatin Immunoprecipitation System (Cat no:
49-2024) following manufacturers protocol, except that
antibodies and the chromatin DNA were incubated overnight. 5
µg of anti-OVOL2 (Santa Cruz Biotechnology, Cat no:
sc-85803 X) or anti-V5 (abcam Cat no: ab9116) antibodies
were used per sample. For the analysis of the chromatin DNA
fragments by qPCR we designed custom primers/probes using
Applied Biosystems’ Primer Express software (Table 2).
RNA-seq data analysis
Sequencing was performed by the UM DNA sequencing
core, using the Illumina Hi-Seq platform to generate 50 base,
paired-end reads. We downloaded and concatenated the
individual reads files to correspond with individual samples.
These fastq files are GEO dataset (GSE48230). We aligned
the reads to the reference transcriptome (UCSC hg19) using
TopHat2.0.2, which is part of the tuxedo next-generation
sequencing data analysis suite [36,37]. We used default
parameter settings with the exception that we specified “–b2-
very-sensitive”. We used FastQC (http://
www.bioinformatics.babraham.ac.uk/projects/fastqc/) to assess
a range of quality measures, and found overall very good
quality aligned reads in each sample. We then used
CuffDiff2.0.2, also part of the tuxedo suite, to assess differential
expression between groups (PC3-EMT14, PC3-EMT14-
OVOL1, PC3-EMT14-OVOL2, and PC3-Epi), using the UCSC
hg19.gtf transcriptome, with -u, -N, --compatible-hits-norm, and
-b (relative to the UCSC hg19.fa) parameter settings. We used
a locally derived Perl script to identify genes/transcripts as
being differentially expressed if they showed: “OK” test status
AND FDR ≤ 0.05, AND fold change (≥ 2.0 or ≤ 0.50).
Enrichment Analysis
We submitted various gene sets to ConceptGen [21] for
enrichment analysis. ConceptGen tests for enrichment across
a broad set of annotations, using a modified Fisher Exact test
to assess significance of enrichment.
Table 2. Primers/probes designed using Applied Biosystems’ Primer Express software for the qPCR analysis of the
immunoprecipitated chromatin DNA.
Names Forward Primer Reverse Primer Probe
(-)4848 CTCAGGTAGAGGAACGAAGCTAGAG GCTTTGGCAAATGATCAGAGAA CAGGGAATAGAATAAATATC (MGB)
(-)3503 TTCCTGACTCAATGACTGCAGAA CCCATAAAGCCGCTACTCAATT CCATTGCCCTCCTTTGTTCCACGG (TAMRA)
(-)2012 CAGGCCAGAAAGAGAACATGAGA TTTCCAGCTCTATCACACATTTTACC AATGCTATTTGTAATACCTCC (MGB)
(-)1389 AAATCCTGCCATAGAAGTGACAAAA GTGACCGGAGTATTGGAAATAACG TATTGAGCACCTACTATGTGTCAT (MGB)
(-)765 GGTATTACTCATTCCGCTCTACTAAGG CCGGGATGGGAAGTGACTT TTTCAATCCAGCTGAAGTT (MGB)
(-)115 CAAGGTTCCGGCCGTAGA CCCACCGCACCTGGTTTA AAAGCCGGGAGTGTC (MGB)
(+)382 CGCCTCCCTGGACCGTTA CGCCGAAGGGCACAAGA AGCGGCTGTTGCTT (MGB)
doi: 10.1371/journal.pone.0076773.t002
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Statistics
We used a one-tailed Student’s t-test where applicable
(qPCR with overexpression and shRNA, when the results were
predicted before performing experiment). In cases where a
one-tailed test was not appropriate, a two-tailed Student’s t-test
was used (e.g. Mouse studies, miRNA and ChIP qPCR,
invasion/migration assay). All error bars represent ±SEM.
Statistical analysis was performed using Prism GraphPad. A
value of P < 0.05 was considered significant.
In vivo statistics
Tumor growth for each model was analyzed using a linear
mixed model. The natural log transformed ROI was fit using a
random slope and intercept. Each model was found to have a
1st-degree heterogeneous autoregressive covariance structure.
Type 3 effects for the model and multiple-comparison adjusted
least square means are given for the comparisons of interest
for each experiment. Additionally, the time by cell line
interaction was ‘sliced,’ in the sense that each comparison was
also examined at each time point. For the survival component
of each experiment, Kaplan-Meier plots were created and log
rank values for these plots are reported. Pairwise log rank
values adjusted for multiple comparisons for the comparisons
of interest were also completed. A value of P < 0.05 was
considered significant.
Supporting Information
Figure S1.  Macrophages induce EMT in epithelial prostate
cancer PC3-Epi cells. Related to Figure 1.
(A) Schematic: Human CD14+ blood monocytes (3x106 cells)
were isolated from healthy donors and induced to differentiate
into M1 or M2 macrophages upon stimulation with INFγ or
interleukin (IL)-4 respectively (100 ng/ml) for 36-42 hours. Next,
these cells were co-cultured with 3x105 highly epithelial
prostate cancer cells (PC3-Epi) for 4 days.
(B) Immunoblot: Shows downregulation of E-cad with the
concomitant upregulation of vimentin in the cancer cell
population from the co-culture with IL-4-treated CD14+
macrophages as compared to controls. The immunoblot is
representative of two independent experiments with similar
results.
(C) Flow Cytometry: Depicts a decrease in the cell surface
expression of the Epithelial Cell Adhesion Molecule (EpCAM)
in the stable mesenchymal PC3-EMT14 prostate cancer cells
compared to the parental epithelial PC3-Epi cells. The results
are representative of two experiments.
(TIF)
Figure S2.  OVOL and ZEB TFs are inversely regulated in
the stable epithelial (PC3-Epi) and the stable mesenchymal
(PC3-EMT14) prostate cancer cells. OVOL2 binds to ZEB1
promoter. Related to Figure 2.
(A) qPCR: mRNA expression in PC3-EMT14 relative to PC3-
Epi prostate cancer cells.
(B) Flow Cytometry: Depicts the cell surface expression of the
transmembrane protein Tetraspanin-8 (TSPAN8) in the
epithelial PC3-Epi cells transduced with a TSPAN8 expression
lentivirus and compared to the parental PC3-Epi cells.
(C) qPCR: Relative mRNA expression of E-cad and the
transcription factors OVOL1, OVOL2 and ZEB1 in the epithelial
PC3-Epi cells transduced with the TSPAN8 expression
lentivirus or with the empty vector control. The graph depicts
the effect of TSPAN8 overexpression in the induction of EMT
as shown by a decrease in E-cad and the OVOL-TFs with the
concomitant increase in ZEB1.
(D) Immunoblot: Overexpression of TSPAN8 partially induces
EMT in the epithelial PC3-Epi cells. TSPAN8 overexpression
upregulates ZEB1 and Vimentin proteins and downregulates E-
cad compared to the control epithelial PC3-Epi-EV cells. The
stable mesenchymal PC3-EMT14 cells are also shown.
(E) qPCR: Analysis of TSPAN8 overexpression in the epithelial
prostate cancer DU145 cells. Similar experiment as shown in
(C) demonstrates the effect of TSPAN8 expression in the
induction of EMT.
(F) ChIP qPCR: The graph on the left represents the input
chromatin of PC3-EMT14-OVOL2 relative to empty vector (EV)
control, and demonstrates that similar amounts of DNA were
used. The graph on the right depicts the ChIP DNA using V5
antibody. The V5 epitope was included at the C-terminus of the
expressed OVOL2. Primers used are named for their forward
primer (see panel I). Results were normalized to input controls
and graphs are relative to EV. Graphs show mean +/- sem; p-
values are represented as *** p < 0.001.
The qPCRs and immunoblots are representative of two
independent experiments with similar results.
(TIF)
Figure S3.  Mesenchymal cancer cells show decreased
mouse survival in the ICI model, while not requiring MET
for solid tumor formation. Related to Figure 3.
(A) IHC: ZEB1 or E-cad staining in subcutaneous tumors. Note
the high E-cad and low ZEB1 staining in the epithelial PC3-Epi
compared to the mesenchymal PC3-EMT12, and PC3-EMT14.
Scale bars are 50 µm.
(B) Tumor burden: Mice received subcutaneous injections and
were imaged weekly for 49 days. Luciferase expression is
represented as regions of interest (ROI-photons/s) as
described in methods. No significant (n.s.) differences in tumor
growth were observed between the mesenchymal (PC3-
EMT12, and PC3-EMT14) and epithelial (PC3-Epi) cells lines.
(C) Kaplan Meier survival curves: Survival was recorded in ICI-
inoculated mice with PC3-Epi, PC3-EMT12, and -EMT14.
(D) IHC: Simultaneous ZEB1 and E-cad expression in PC3-
EMT12 tumors found in liver and bone from mice given ICI.
Scale bar represents 100 µm.
(E) IHC: Simultaneous ZEB1 and E-cad staining of metastases
sections from liver corresponding to mice ICI with PC3-Epi and
PC3-EMT14 cells. Note that PC3-Epi predominately retained
its epithelial phenotype, and similarly PC3-EMT14 retained its
mesenchymal phenotype. Scale bars are 100 µm (black) and
20 µm (red).
The IHCs show a representative staining of one out of three
sections with similar results.
(TIF)
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Figure S4.  OVOL expression in mesenchymal cancer cells
induces MET and forms epithelial tumors. Related to Figure
4.
(A) IHC: E-cad and ZEB1 staining of orthotopic tumors from
PC3-EMT14 expressing OVOL1 or OVOL2 and the control.
Note that tumors predominantly preserved their mesenchymal
(PC3-EMT14) or epithelial (PC3-EMT14-OVOL1 and OVOL2)
cell origins. Scale bar represents 100 µm.
(B) IHC: E-cad, and Ki-67 staining of metastatic (peritoneum)
tumor from a mouse that received an orthotopic injection with
PC3-EMT14 cells. The Ki-67 staining of E-cad negative tumor
cells demonstrates that these mesenchymal cells can
proliferate without undergoing MET. Scale bar represents 100
µm.
The IHCs show a representative staining of one out of three
sections with similar results.
(TIF)
Figure S5.  OVOL1 and OVOL2 expression correlates with
hallmark genes of epithelial differentiation in 917 cancer
cell lines. Related to Figure 5.
(A) Oncomine: Gene expression analysis of the Barretina study
(917 cancer cell lines) shows a significant correlation between
OVOL2 and a number of epithelial associated genes including
ESRP1, ESRP2, and E-cad (referred to as CDH1 on the
microarray)). Within this set of genes OVOL1 (not shown)
demonstrates a 0.76 correlation with OVOL2.
(B) Heat map: The top 100 genes identified in Figure 5B when
comparing PC3-Epi, PC3-EMT14-OVOL1 and PC3-EMT14-
OVOL2 relative to PC3-EMT14. The differential regulation (Up
(red) and down (blue)) of individual genes appears to be
conserved across all three epithelial cell lines.
(C) Schematic: Protein isoforms resulting from the alternative
splicing of EPB41L5 induced by OVOL2. The isoform switching
was identified by RNA-seq. Blue boxes represent conserved
amino acid sequences, while red boxes represent unique
sequences of the isoforms 1 and 4 that show upregulation in
mesenchymal (EMT) or epithelial (MET) cells, respectively.
(TIF)
Table S1.  Ingenuity Pathway Analysis (IPA) of EMT cells
isolated from macrophage co-cultures. Related to Figure 1.
Ingenuity Pathway analysis identified molecular functions
associated with EMT like cellular movement (50 molecules),
cellular and tissue development (37 molecules), and cell death
(58 molecules). Function associated with cell-to-cell signaling
and interaction (as occurred between cancer cells and
macrophages) was also identified (49 molecules).
(DOCX)
Table S2.  Genes that positively correlate (>0.74) with
OVOL1 and OVOL2 expression in 917 cancer cell lines.
Related to Figure 5. The table depicts the genes that correlate
(r > 0.74) with OVOL1 and OVOL2 expression in 917 human
cancer cell lines (Barretina study). Note the high correlation of
E-cad, ESRP1 and ESRP2 with both OVOL1 and OVOL2
expression.
(DOCX)
Table S3.  ConceptGen analysis of common pathways
associated with OVOL1 and OVOL2 induced MET
signature in prostate cancer cells. Related to Figure 5.
ConceptGen analysis of the RNA-seq results showing the
common pathways associated with genes that are differentially
expressed in PC3-EMT14-OVOL1 and PC3-EMT14-OVOL2,
relative to PC3-EMT14.
(DOCX)
Table S4.  Genes that negatively correlate (r < -0.5) with
OVOL1 and OVOL2 expression in 917 cancer cell lines.
Related to Figure 5. Depicts the common genes that negatively
correlate (r < -0.5) with OVOL1 and OVOL2 expression in the
Barretina study (917 human cancer cell lines).
(DOCX)
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